ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1378

Presence of Anti-RNA Polymerase 3 Antibody in Systemic Sclerosis, Renal Disease, Malignancy and ILD from a Single Academic Center Cohort

Matthew Kirkpatrick1, Janet Lee1, Anne Tebo2, Haojia Li1, yue zhang1 and Tracy Frech1, 1University of Utah, Salt Lake City, UT, 2Department of Laboratory Medicine and Pathology, Mayo Clinic College of Medicine, Rochester, MN

Meeting: ACR Convergence 2021

Keywords: Autoantibody(ies), Scleroderma, Systemic sclerosis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 8, 2021

Title: Systemic Sclerosis & Related Disorders – Clinical Poster II (1364–1390)

Session Type: Poster Session C

Session Time: 8:30AM-10:30AM

Background/Purpose: Autoantibodies are included in the disease classification criteria for systemic sclerosis (SSc). Our group previously reported the level of topoisomerase autoantibody as an important factor for disease classification (Tebo, et al, J. Rheumatology, 46(4) 440-442, 2019). This project analyzed the level of anti-RNA polymerase 3 (RNApol3) antibodies in a cohort of patients assessed for autoimmune disease at a large academic institution.

Methods: 1555 patients were assessed for autoimmune disease under IRB #00029507. RNApol3 antibody positivity (≥20 units) was detected in 132 patients. Two investigators manually reviewed the clinical records for these patients and recorded age, sex, disease classification and disease features. The statistical hypothesis testing methods for age, gender, and RNApol3 are Student’s t-test, Fisher’s exact test and Wilcoxon rank-sum test, respectively.

Results: Among the 132 patients with a positive RNApol3 antibody, 80 did not meet classification criteria for SSc at the time of the assessment (Table 1). The 52 patients that did meet criteria for SSc had a higher level of RNApol3 antibody, with an optimal cut-off level of 27 units (Figure 1). Age and sex were not significantly different in the two groups of RNApol3 antibody positive patients with and without SSc. In the SSc patient population, age and RNApol3 level >81 units was significantly correlated with the presence of renal insufficiency (Figure 1). The presence of malignancy and ILD was significantly correlated to age but not level of RNApol3 antibody.

Conclusion: Our study supports that the level RNApol3 antibody may be important in classification criteria for SSc. Similarly, in the SSc cohort of patients with a positive RNApol3 antibody, the level may correlate with renal insufficiency. Our study did not find that the level of RNApol3 antibody correlated with ILD or malignancy.

Table 1: Clinical and laboratory characteristics of patients with RNApol3 positivity. Descriptive statistics used for age and gender are Mean(SD) and Number(%)

Figure 1: ROC curves and AUCs with 95% CIs (DeLong method). The red dots refer to the false positive rate (FPR) and true positive rate (TPR) of the optimal cutpoint.


Disclosures: M. Kirkpatrick, None; J. Lee, None; A. Tebo, None; H. Li, None; y. zhang, None; T. Frech, None.

To cite this abstract in AMA style:

Kirkpatrick M, Lee J, Tebo A, Li H, zhang y, Frech T. Presence of Anti-RNA Polymerase 3 Antibody in Systemic Sclerosis, Renal Disease, Malignancy and ILD from a Single Academic Center Cohort [abstract]. Arthritis Rheumatol. 2021; 73 (suppl 9). https://acrabstracts.org/abstract/presence-of-anti-rna-polymerase-3-antibody-in-systemic-sclerosis-renal-disease-malignancy-and-ild-from-a-single-academic-center-cohort/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2021

ACR Meeting Abstracts - https://acrabstracts.org/abstract/presence-of-anti-rna-polymerase-3-antibody-in-systemic-sclerosis-renal-disease-malignancy-and-ild-from-a-single-academic-center-cohort/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology